---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029021"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:10:50.910988+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M

## Summary
- Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).
- Q4 net income $7.7M ($0.05 diluted EPS) vs net loss $0.6M; adjusted net income $8.8M vs $1.9M.
- FY24 revenue $482.0M (+11%); net income $0.9M vs $4.9M; adjusted net income $20.5M vs $12.7M.
- Cash $136.2M, zero debt (vs $104.3M cash and $66.2M net debt year-end 2023).
- FY25 guidance: revenue $480-535M; net income $9.5-38.8M; Adj. EBITDA $43.6-83.2M; ReNu BLA submission targeted by year-end.

## SEC filing metadata
- accession: 0000950170-25-029021
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017025029021/0000950170-25-029021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017025029021/orgo-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029021
- JSON: https://secwatch.observer/filing/0000950170-25-029021.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.